Scientists are just starting to tease out the microbiome’s role in CAR-T outcomes among cancer patients
As cancer-killing CAR-T cells course through the body, they make occasional pit stops at the gut. What they do there — and which gut microbes they meet up with — could potentially change the prospects of these engineered immune cells.
Scientists are just beginning to tease apart the conditions that might lead to a gut microbiome to influence how well CAR-T therapy works.
